
Sign up to save your podcasts
Or


An AHA review: the OPTION, SUMMIT, VANISH 2, SARAH, and CLEAR trials are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. OPTION Trial
For AF, LAA Rivals Anticoagulants After Ablation
https://www.medscape.com/viewarticle/af-laa-rivals-anticoagulants-after-ablation-2024a1000l7n
4 Reasons to Question Percutaneous Left Atrial Appendage Closure After AF Ablation
https://www.medscape.com/viewarticle/4-reasons-question-percutaneous-left-atrial-appendage-2024a1000l0u
II. SUMMIT Trial
Tirzepatide Reduces Heart Failure Events in HFpEF With Obesity
https://www.medscape.com/viewarticle/tirzepatide-reduces-heart-failure-events-hfpef-obesity-2024a1000kx5
III. VANISH Trial
New Trial Result Pushes Past Antiarrhythmic Therapy After MI
https://www.medscape.com/viewarticle/new-trial-result-pushes-past-antiarrhythmic-therapy-after-mi-2024a1000l08
IV. Cardioprotection
Common Heart Failure Drugs Ease Heart Damage During Chemo https://www.medscape.com/viewarticle/common-heart-failure-drugs-ease-heart-damage-during-chemo-2024a1000l14
V. CLEAR trial
Spironolactone Shows Mixed Results in Acute MI
https://www.medscape.com/viewarticle/spironolactone-shows-mixed-results-acute-mi-2024a1000l41
Routine Colchicine or MRA Post-MI: No CLEAR Benefit
https://www.medscape.com/viewarticle/routine-colchicine-or-mra-post-mi-no-clear-benefit-2024a1000la2
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
By Medscape4.9
862862 ratings
An AHA review: the OPTION, SUMMIT, VANISH 2, SARAH, and CLEAR trials are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. OPTION Trial
For AF, LAA Rivals Anticoagulants After Ablation
https://www.medscape.com/viewarticle/af-laa-rivals-anticoagulants-after-ablation-2024a1000l7n
4 Reasons to Question Percutaneous Left Atrial Appendage Closure After AF Ablation
https://www.medscape.com/viewarticle/4-reasons-question-percutaneous-left-atrial-appendage-2024a1000l0u
II. SUMMIT Trial
Tirzepatide Reduces Heart Failure Events in HFpEF With Obesity
https://www.medscape.com/viewarticle/tirzepatide-reduces-heart-failure-events-hfpef-obesity-2024a1000kx5
III. VANISH Trial
New Trial Result Pushes Past Antiarrhythmic Therapy After MI
https://www.medscape.com/viewarticle/new-trial-result-pushes-past-antiarrhythmic-therapy-after-mi-2024a1000l08
IV. Cardioprotection
Common Heart Failure Drugs Ease Heart Damage During Chemo https://www.medscape.com/viewarticle/common-heart-failure-drugs-ease-heart-damage-during-chemo-2024a1000l14
V. CLEAR trial
Spironolactone Shows Mixed Results in Acute MI
https://www.medscape.com/viewarticle/spironolactone-shows-mixed-results-acute-mi-2024a1000l41
Routine Colchicine or MRA Post-MI: No CLEAR Benefit
https://www.medscape.com/viewarticle/routine-colchicine-or-mra-post-mi-no-clear-benefit-2024a1000la2
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]

1,877 Listeners

319 Listeners

544 Listeners

708 Listeners

502 Listeners

167 Listeners

14 Listeners

16 Listeners

3,384 Listeners

138 Listeners

1,143 Listeners

65 Listeners

521 Listeners

367 Listeners

61 Listeners

25 Listeners

7 Listeners

259 Listeners

440 Listeners

272 Listeners